MX2012004416A - Sistemas polimericos para el suministro de agentes anticancer. - Google Patents

Sistemas polimericos para el suministro de agentes anticancer.

Info

Publication number
MX2012004416A
MX2012004416A MX2012004416A MX2012004416A MX2012004416A MX 2012004416 A MX2012004416 A MX 2012004416A MX 2012004416 A MX2012004416 A MX 2012004416A MX 2012004416 A MX2012004416 A MX 2012004416A MX 2012004416 A MX2012004416 A MX 2012004416A
Authority
MX
Mexico
Prior art keywords
methacrylamide
anticancer agents
compositions
delivery
attached
Prior art date
Application number
MX2012004416A
Other languages
English (en)
Inventor
Young Bok Lee
Chang Ho Ahn
Deog Joong Kim
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of MX2012004416A publication Critical patent/MX2012004416A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las composiciones para el tratamiento de tejidos cancerosos en animales de sangre caliente que contienen uno o dos agentes anticáncer unidos a los portadores poliméricos que tienen unidades de monómero derivadas de uno o más de N-(2-carboxipropil) metacrilamida (2- CPMA, por sus siglas en inglés), N-(3-carboxipropil) metacrilamida (3-CPMA, por sus siglas en inglés), N-(2- aminopropil) metacrilamida (2-APMA, por sus siglas en inglés) y/o N-(3-aminopropil) metacrilamida (3-APMA, por sus siglas en inglés) que también están incluidos. Los agentes anticáncer en las composiciones pueden unirse al portador polimérico por las cadenas laterales que pueden ser susceptibles a la hidrólisis por las enzimas lisosomales intracelularmente. Las composiciones también pueden incluir un ligando de direccionamiento unido al portador polimérico, opcionalmente con un segundo conector.
MX2012004416A 2009-10-13 2010-10-13 Sistemas polimericos para el suministro de agentes anticancer. MX2012004416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25115609P 2009-10-13 2009-10-13
PCT/US2010/052510 WO2011047051A2 (en) 2009-10-13 2010-10-13 Polymeric systems for the delivery of anticancer agents

Publications (1)

Publication Number Publication Date
MX2012004416A true MX2012004416A (es) 2012-05-08

Family

ID=43855047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004416A MX2012004416A (es) 2009-10-13 2010-10-13 Sistemas polimericos para el suministro de agentes anticancer.

Country Status (11)

Country Link
US (2) US8846110B2 (es)
EP (1) EP2488207A4 (es)
JP (2) JP5749273B2 (es)
KR (2) KR101721865B1 (es)
CN (2) CN102686243B (es)
AU (1) AU2010306917B2 (es)
BR (1) BR112012008772A2 (es)
CA (1) CA2777397C (es)
IL (1) IL218991A0 (es)
MX (1) MX2012004416A (es)
WO (1) WO2011047051A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434610B2 (en) * 2008-10-07 2016-09-06 Rexahn Pharmaceuticals, Inc. HPMA—docetaxel conjugates and uses therefore
JP5944836B2 (ja) * 2010-03-08 2016-07-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 高分子薬物送達結合体ならびにその製造および使用方法
US8426143B2 (en) * 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
EP3324930A2 (en) 2015-09-16 2018-05-30 DFB Soria, LLC Delivery of drug nanoparticles and methods of use thereof
GB2551979A (en) * 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates
CN106581690B (zh) * 2016-12-23 2019-05-28 四川大学 肿瘤微环境刺激可降解的两亲性嵌段hpma聚合物给药***及其制备方法
CN110636833B (zh) 2017-03-15 2024-07-09 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
CN112165949A (zh) 2018-03-16 2021-01-01 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗宫颈上皮内瘤变(cin)和***的局部疗法
CN108359052B (zh) * 2018-04-24 2020-11-17 辽宁大学 一种藤黄酸-叶酸-hpma高分子聚合物及其制备方法和应用
CN112535735B (zh) * 2019-09-23 2021-09-03 四川大学 一种可同时放大免疫原性细胞死亡以及增强抗肿瘤效果的联合用药物
EP4194010A1 (en) * 2020-08-04 2023-06-14 Progeneer Inc. Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074039A (en) 1970-03-26 1978-02-14 Ceskoslovenska Akademie Ved Hydrophilic N,N-diethyl acrylamide copolymers
US3997660A (en) 1972-02-29 1976-12-14 Ceskoslovenska Akademie Ved Soluble hydrophilic polymers and process for producing the same
CS159937B1 (es) 1972-02-29 1975-02-28
CS158458B1 (es) 1972-05-02 1974-11-25
CS173846B1 (es) 1974-04-23 1977-03-31
CS173849B1 (es) 1974-04-25 1977-03-31
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
JP2001513078A (ja) 1996-12-30 2001-08-28 バテル・メモリアル・インスティテュート 吸入により新生物を治療する製剤とその方法
US5965118A (en) 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6346349B1 (en) 1999-02-11 2002-02-12 Alcatel Anode invention for lithium/transition metal fluoride molten salt cells and batteries
US20010041189A1 (en) 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
BR0010017A (pt) 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1466627A1 (en) 1999-10-12 2004-10-13 Cell Therapeutics, Inc. Polyglutamate camptothecin conjugates
KR100729015B1 (ko) 2000-01-04 2007-06-14 어섹스 팔마큐티칼스 인코포레이티드 Ｎ,ｏ-아미도말로네이트 백금 착화합물
US7166733B2 (en) 2000-01-04 2007-01-23 Access Pharmaceuticals, Inc. O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
GB0018240D0 (en) 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
CA2445985A1 (en) 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
AU2002357726A1 (en) 2001-11-15 2003-06-10 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore
WO2003101425A2 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
WO2004062588A2 (en) 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
FR2858936A1 (fr) 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
WO2006012355A2 (en) 2004-06-28 2006-02-02 University Of Maryland, Baltimore Radiolabeled nanohybrids targeting solid tumor neovasculature and method of using same
EP1812864A2 (en) 2004-10-07 2007-08-01 Emory University Multifunctional nanoparticles conjugates and their use
CA2606270A1 (en) 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
WO2007067417A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
CZ298945B6 (cs) 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
US8017141B2 (en) 2006-12-15 2011-09-13 Advanced Cardiovascular Systems, Inc. Coatings of acrylamide-based copolymers

Also Published As

Publication number Publication date
CN104587484A (zh) 2015-05-06
KR20120114221A (ko) 2012-10-16
US20110086111A1 (en) 2011-04-14
CA2777397A1 (en) 2011-04-21
KR101721865B1 (ko) 2017-04-03
WO2011047051A3 (en) 2011-08-18
JP2013507452A (ja) 2013-03-04
EP2488207A4 (en) 2015-06-10
US8846110B2 (en) 2014-09-30
BR112012008772A2 (pt) 2017-06-20
KR20150058554A (ko) 2015-05-28
AU2010306917A1 (en) 2012-04-26
AU2010306917B2 (en) 2014-11-27
JP2015110622A (ja) 2015-06-18
IL218991A0 (en) 2012-06-28
JP5749273B2 (ja) 2015-07-15
CA2777397C (en) 2017-08-29
CN102686243A (zh) 2012-09-19
WO2011047051A2 (en) 2011-04-21
US20150071872A1 (en) 2015-03-12
EP2488207A2 (en) 2012-08-22
CN102686243B (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
MX2012004416A (es) Sistemas polimericos para el suministro de agentes anticancer.
ZA202003211B (en) A conjugate of a tubulysin analog with branched linkers
SG10201804331TA (en) Oligonucleotide conjugates
MX365521B (es) Polimeros que contienen zwiteriones de alto peso molecular.
WO2008106129A3 (en) Polymeric micelles for combination drug delivery
IN2015DN00255A (es)
MX2007012157A (es) Micelas polimericas para suministro de farmacos.
WO2007076371A3 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
MX2013006100A (es) Agente terapeutico que induce citotoxicidad.
WO2013012476A3 (en) Branched polyether-polyamide block copolymers and methods of making and using the same
MX368966B (es) Conjugados de proteina-polimero-farmaco.
NZ608387A (en) Prodrugs comprising an exendin linker conjugate
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
JO2932B1 (en) Lyspro insulin compounds linked to PEG
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
EP2166991A4 (en) PVA-PAA HYDROGELS
EP2538979A4 (en) COMPLEX ADHESIVE CO-STORES PRODUCED FROM ELECTROSTATICALLY ASSOCIATED BLOCK COPOLYMERS AND METHODS OF MANUFACTURING AND USING THE SAME
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
MX2011004085A (es) Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
MX2011012643A (es) 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal.
GB2451599A (en) Nanostructures suitable for delivery of agents
WO2011046596A3 (en) Anti-cancer tamoxifen-melatonin hybrid ligand
WO2011113065A3 (en) Pegylated polyplexes for polynucleotide delivery
WO2011163512A3 (en) Cancer therapy

Legal Events

Date Code Title Description
FG Grant or registration